Ma­jor dereg­u­la­tion? FDA with­draws sev­er­al rules and reg­u­la­tions re­lat­ed to med­ical prod­ucts

Al­most a year ago, Pres­i­dent Don­ald Trump told phar­ma­ceu­ti­cal ex­ec­u­tives that his ad­min­is­tra­tion would cut 75% to 80% of FDA reg­u­la­tions, “at a lev­el no one has ever seen be­fore.”

Since those com­ments last Jan­u­ary, the FDA has with­drawn the most rule­mak­ings of any De­part­ment of Health and Hu­man Ser­vices agency, though on­ly a hand­ful are re­lat­ed to med­ical prod­ucts (the oth­ers are to­bac­co re­lat­ed) and it’s un­clear how the with­draw­al of these pro­pos­als and reg­u­la­tions so far in 2017 will im­pact pa­tient safe­ty or in­dus­try bur­dens.

new re­port from the non­prof­it Pub­lic Cit­i­zen, re­leased this week, dis­cuss­es not on­ly the reg­u­la­tions with­drawn in 2017 but how this ad­min­is­tra­tion “has done a lot to slow down or stop on­go­ing rule­mak­ings.”

For in­stance, ac­cord­ing to HHS’ reg­u­la­to­ry agen­da pub­lished in Au­gust, the fi­nal­iza­tion of a rule on drug la­bels, “to re­flect cer­tain types of new­ly ac­quired in­for­ma­tion in ad­vance of FDA’s re­view of such changes,” has been pushed back in­def­i­nite­ly, the fi­nal­iza­tion of a rule re­lat­ed to ac­cept­ing cer­tain clin­i­cal da­ta to bring new med­ical de­vices to mar­ket has been de­layed to next month and the fi­nal­iza­tion of an FDA rule on post­mar­ket­ing safe­ty re­quire­ments has been pushed back to Oc­to­ber 2018.

And since Trump took of­fice, with­drawals of rule­mak­ings and reg­u­la­tions re­lat­ed to med­ical prod­ucts oc­curred last April and June and in­clude one on pa­tient la­bel­ing, “to help pa­tients use their pre­scrip­tion drug prod­ucts safe­ly and ef­fec­tive­ly”; an­oth­er on clin­i­cal tri­als that would have up­dat­ed the in­ves­ti­ga­tion­al new drug (IND) ap­pli­ca­tion reg­u­la­tions to “bet­ter pro­tect the rights, safe­ty, and wel­fare of sub­jects and help en­sure the in­tegri­ty of clin­i­cal tri­al da­ta”; a third on up­dat­ing and har­mo­niz­ing cur­rent good man­u­fac­tur­ing prac­tice (cGMP) reg­u­la­tions for fin­ished phar­ma­ceu­ti­cals; a fourth to re­vise reg­u­la­tions for cGMP with re­gard to com­po­nents used in man­u­fac­tur­ing fin­ished phar­ma­ceu­ti­cals; and a fifth that would have reg­u­lat­ed the for­mat and con­tent of re­ports in­tend­ed to demon­strate sub­stan­tial equiv­a­lence.

But on the top­ic of whether 75% to 80% of FDA reg­u­la­tions will be cut mov­ing for­ward, a White House spokesman re­ferred Fo­cus to FDA, which re­ferred Fo­cus to this blog post from An­na Abram, FDA’s deputy com­mis­sion­er, on con­sid­er­a­tions the agency takes in de­ter­min­ing which rule­mak­ings to with­draw.

The post high­lights com­ments sought by FDA on which rule­mak­ings could be mod­i­fied, re­pealed or re­placed, to re­duce the bur­den on in­dus­try while al­low­ing FDA to con­tin­ue its pub­lic health mis­sion, though ear­li­er this month, FDA Com­mis­sion­er Scott Got­tlieb said a lot of FDA’s reg­u­la­tions are de-reg­u­la­to­ry in na­ture so they do not need to be cut.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Brent Saunders [Getty Photos]

UP­DAT­ED: Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

Re­gen­eron and their part­ners at Sanofi have beat the No­var­tis/Roche team to the punch on an­oth­er key in­di­ca­tion for their block­buster an­ti-in­flam­ma­to­ry drug Dupix­ent. The drug team scored an ac­cel­er­at­ed FDA ap­proval for chron­ic rhi­nos­i­nusi­tis with nasal polyps, mak­ing this the first such NDA for the field.

An­a­lysts have been watch­ing this race for awhile now, as Sanofi/Re­gen­eron won a snap pri­or­i­ty re­view for what is now their third dis­ease in­di­ca­tion for this treat­ment. And they’re not near­ly done, build­ing up hopes for a ma­jor fran­chise.

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

Back in 2014, Stephanie Tagliatela opted to take an early exit out of her PhD program after working in Mark Bear’s lab at MIT, where she specialized in the synaptic connections between neuronal cells in the brain. She never finished that PhD, but she and fellow MIT student Kartik Ramamoorthi — who was on the founding team at Voyager — came away with some ideas for a gene therapy startup.

Today, fully 5 years later, she and Ramamoorthi are taking the wraps off of a $104 million mega-round designed to take the cumulative work of their preclinical formative stage for Encoded Therapeutics into human studies. They’ve now raised $158 million since starting out in Illumina’s incubator in the Bay Area, and they believe they are firmly on track to do something unique in gene therapy.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

Richard Gonzalez testifying in front of Senate Finance Committee, February 2019 [AP Images]

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

Big time M&A is back. But for how long?

Over the past 18 months we’ve now seen three major buyouts announced: Takeda/Shire; Bristol-Myers/Celgene and now AbbVie/Allergan. And with this latest deal it’s increasingly clear that the sharp fall from grace suffered by high-profile players which have seen their share prices blasted has created an opening for the growth players in big pharma to up their game — in sharp contrast to the popular bolt-on deals that have been driving the growth strategy at Novartis, Merck, Roche and others.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Two biotech uni­corns swell pro­posed IPOs, eye­ing a $600M-plus wind­fall

We’ve been wait­ing for the ar­rival of Bridge­Bio’s IPO to top off the wave of new biotech of­fer­ings sweep­ing through Nas­daq at the end of H1. And now we learn that it’s been sub­stan­tial­ly up­sized.

Ini­tial­ly pen­ciled in at a uni­corn-sized $225 mil­lion, the KKR-backed biotech has spiked that to the neigh­bor­hood of $300 mil­lion, look­ing to sell 20 mil­lion shares at $14 to $16 each. That’s an added 5 mil­lion shares, re­ports Re­nais­sance Cap­i­tal, which fig­ures the pro­posed mar­ket val­u­a­tion for Neil Ku­mar’s com­pa­ny at $1.8 bil­lion.

No­var­tis holds back the copy­cat brigade's at­tack on its top drug fran­chise — for now

A fed­er­al judge has put a gener­ic chal­lenge to No­var­tis’ block­buster mul­ti­ple scle­ro­sis drug Gilenya on hold while a patent fight plays out in court.

Judge Leonard P. Stark is­sued a tem­po­rary in­junc­tion ear­li­er this week, forc­ing My­lan, Dr. Red­dy’s Lab­o­ra­to­ries and Au­robindo Phar­ma to shelve their launch plans to al­low the patent fight to pro­ceed. He ruled that al­low­ing the gener­ics in­to the mar­ket now would per­ma­nent­ly slash the price for No­var­tis, even if it pre­vails. 

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

Af­ter get­ting beat up on all sides from mar­ket ob­servers who don’t much care for the lat­est mega-deal to ar­rive in bio­phar­ma, at least one promi­nent an­a­lyst now is start­ing to like what he sees in the num­bers for Ab­b­Vie/Al­ler­gan.

But it’s go­ing to take some en­cour­age­ment if Ab­b­Vie ex­ecs want it to last.

Ab­b­Vie’s mar­ket cap de­clined $20 bil­lion on Tues­day as the stock took a 17% hit dur­ing the day. And SVB Leerink’s Ge­of­frey Porges can see a dis­tinct out­line of an up­side af­ter re­view­ing the fun­da­men­tals of the deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

While Ako­rn works to re­vive its for­tunes, the FDA hits it with an­oth­er warn­ing let­ter

Ako­rn just can’t dig it­self out of its hole.

The spe­cial­ty gener­ic drug­mak­er has re­ceived yet an­oth­er warn­ing let­ter from the FDA this year. With­out dis­clos­ing any specifics, the Lake For­est, Illi­nois-based drug­mak­er on Wednes­day said the US reg­u­la­tor had is­sued the let­ter, cit­ing an in­spec­tion of its Som­er­set, New Jer­sey man­u­fac­tur­ing fa­cil­i­ty in Ju­ly and Au­gust of 2018. The com­pa­ny’s shares $AKRX dipped about 1.7% to $4.65 be­fore the bell.